Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

E-therapeutics plc

Headquarters: Long Hanborough, Oxfordshire, United Kingdom
Year Founded: 2001
Status: Private

BioCentury | Apr 22, 2024
Regulation

Defending accelerated approval. Plus: endpoint innovation & AIM amiss: a BioCentury podcast

Why it’s wrong to conclude half of cancer accelerated approvals are useless
BioCentury | Apr 22, 2024
Finance

Delisting biotechs take AIM at U.K. exchange

What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

BioCentury | Jul 15, 2017
Company News

Management tracks

BioCentury | Jul 13, 2017
Strategy

Everyone counts in GWAS

New study on GWAS argues for drugging complex circuits not single targets
BioCentury | Jul 18, 2016
Company News

Management tracks

BioCentury | Feb 22, 2016
Clinical News

Tramadol: Phase IIb data

BioCentury | Jun 8, 2015
Clinical News

Dexanabinol: Phase Ib started

BioCentury | May 19, 2014
Clinical News

Dexanabinol: Phase I ongoing

Items per page:
1 - 10 of 24